Abbott (ABT: Quote) and Action Pharma A/S, a privately owned company, have reached an agreement in which Abbott would acquire AP214 from Action Pharma. The company said this acquisition would enhance Abbott's pipeline in renal care. Abbott has two investigational treatments in development for chronic kidney disease.
Pursuant to the deal, Abbott would buy all global rights to develop and commercialize AP214 for the prevention of AKI and other relevant indications. Abbott would provide a cash payment of $110 million to Action Pharma and woul be responsible for funding all future development and commercialization activities regarding AP214. No later milestone payments or royalties would be paid to Action Pharma.
Abbott expects to incur a one-time specified item in the second quarter of 2012, related to this payment.
Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org